Intravitreal injection of a Rho-kinase inhibitor (Fasudil) for recent-onset nonarteritic anterior ischemic optic neuropathy

Nasrin Sanjari, Mohammad Pakravan, Ramin Nourinia, Hamed Esfandiari, Ali Hafezi-Moghadam, Souska Zandi, Shintaro Nakao, Mohamamad Hassan Shah-Heidari, Arsia Jamali, Mehdi Yaseri, Hamid Ahmadieh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This study evaluated the effects of intravitreal injection of fasudil (IVF), a Rho-kinase inhibitor, in cases of recent-onset nonarteritic anterior ischemic optic neuropathy (NAION). In this interventional case series, 13 eyes of 13 patients diagnosed with NAION within 14 days of onset were included. The affected eyes received a 0.025 mg/0.05 mL IVF. Functional and structural outcomes were assessed 1 and 3 months following treatment. Best corrected visual acuity (BCVA) was the main outcome measured, with mean deviation (MD) index of the VF test and peripapillary retinal nerve fiber layer thickness as secondary measures. There was a statistically significant improvement in the patients' BCVA 1 and 3 months following IVF; BCVA improved from 1.69 ± 0.55 logMAR at baseline to 0.98 ± 0.47 and 0.93 ± 0.51 logMAR at 1 and 3 months, respectively (P =.004). The change in BCVA was not significant between month 1 and month 3 (P =.22). Peripapillary retinal nerve fiber layer thickness decreased from 173.5 ± 29.28 μm in the baseline evaluation to 85.8 ± 8.8 μm at 1 month, and 62.9 ± 5.97 μm at 3 months (P =.003). MD values changed from 24.60 ± 3.80 to 21.0 ± 6.10 and 20.5 ± 6.50 at 1 and 3 months, respectively (P =.007 and.005, respectively). This pilot study suggests that IVF may be an effective treatment for patients with recent-onset NAION. Larger studies are required to establish the therapeutic role of fasudil for NAION.

Original languageEnglish
Pages (from-to)749-753
Number of pages5
JournalJournal of Clinical Pharmacology
Volume56
Issue number6
DOIs
Publication statusPublished - Jun 1 2016
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sanjari, N., Pakravan, M., Nourinia, R., Esfandiari, H., Hafezi-Moghadam, A., Zandi, S., ... Ahmadieh, H. (2016). Intravitreal injection of a Rho-kinase inhibitor (Fasudil) for recent-onset nonarteritic anterior ischemic optic neuropathy. Journal of Clinical Pharmacology, 56(6), 749-753. https://doi.org/10.1002/jcph.655